ACCOAST: Pretreatment With Prasugrel in NSTEMI Patients Does Not Reduce Major CV Risks; Increases Bleeding Risks
The study randomly assigned 4,033 NSTEMI patients to receive 30 mg of prasugrel (pretreatment group) or placebo (control group) before their scheduled coronary angiography. When PCI was indicated, an additional 30 mg dose of prasugrel was given to those in the pretreatment group, while 60 mg of prasugrel was given to those in the control group.
In terms of safety, however, the study found significantly higher incidences of TIMI major and life-threatening bleeding complications in the pre-treatment group as compared to the control group. According to the study investigators, bleeding events were largely associated with PCI or CABG and occurred early in those patients that underwent PCI, with the most frequent complications involving bleeding at the access site, pericardial bleeding and retroperitoneal bleeding. While the study investigators did note that bleeding was less frequent in those patients who were younger, had a high body weight and/or had PCI performed through radial access, pretreatment with prasugrel was still consistently linked to excess bleeding in these subgroups.
Overall, the ACCOAST findings suggest that "stronger antiplatelet therapy does not prevent the occurrence of myocardial infarction before catheterization or after PCI," the investigators note. "Our results support the administration of prasugrel when the coronary anatomy is known and after PCI is selected as the treatment strategy."
In an accompanying commentary, John Keaney, Jr., MD, writes that the findings "indicate that one can safely pursue a more parsimonious approach of reserving prasugrel administration until after angiography. With this strategy, P2Y12 treatment can be limited to patients who will be undergoing PCI, and patients with NSTEMI who require CABG will be able to avoid unnecessary delays." Kearny urges news studies to determine whether newer agents, administered only post-angiography, can improve efficiency in treatment of NSTEMI patients.
< Back to Listings